CSIMarket
 
Lantern Pharma Inc   (NASDAQ: LTRN)
Other Ticker:  
 
 
Price: $5.0700 $-0.23 -4.340%
Day's High: $5.5876 Week Perf: 8.57 %
Day's Low: $ 5.00 30 Day Perf: 23.06 %
Volume (M): 64 52 Wk High: $ 11.99
Volume (M$): $ 325 52 Wk Avg: $4.73
Open: $5.55 52 Wk Low: $2.79



 Market Capitalization (Millions $) 55
 Shares Outstanding (Millions) 11
 Employees 22
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Lantern Pharma Inc
Lantern Pharma Inc is a biotechnology company that focuses on using artificial intelligence (AI) and machine learning (ML) in drug discovery and development. The company aims to improve the efficacy and success rate of cancer therapeutics by identifying novel biomarkers and repurposing existing FDA-approved drugs. Lantern Pharma's AI-driven platform helps to predict patient response to specific cancer treatments and enables precision medicine approaches. By leveraging big data analytics, Lantern Pharma aims to accelerate the identification and development of personalized therapies for cancer patients, ultimately leading to better patient outcomes.


   Company Address: 1920 McKinney Avenue Dallas 75201 TX
   Company Phone Number: 277-1136   Stock Exchange / Ticker: NASDAQ LTRN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPMC   -5.85%    
RYTM   -0.39%    
SUPN        2.78% 
TGTX        5.11% 
XNCR   -3.29%    
ZLAB        0.55% 
• View Complete Report
   



Business Update

Promising Advances and Market Challenges Lantern Pharmas Phase 2 HARMONIC Trial for LP-300 in Never-Smoker NSCLC Pat...

Published Mon, Dec 30 2024 10:55 AM UTC

Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company focused on developing targeted cancer therapies, recently announced significant progress in its clinical research initiatives. The company has successfully enrolled its first patient in Taiwan for the Phase 2 HARMONIC clinical trial, which assesses the efficacy of its proprietary compound LP-3...

Business Update

Lantern Pharma Sets New Precedent in NSCLC Treatment with Innovative Expansion in Japan Amid Competitive Landscape

Published Tue, Nov 19 2024 2:47 PM UTC

In an inspiring development for the oncology community, Lantern Pharma Inc. (NASDAQ: LTRN), an emerging leader in targeted cancer therapies powered by artificial intelligence (AI), has announced the dosing of its first patient in Japan as part of the expansion cohort for its Phase 2 HARMONIC clinical trial. This trial critically focuses on LP-300, a novel treatment designed ...

Business Update

Fast-Track to Advanced Cancer Care Lantern Pharmas LP-184 and the Future of Glioblastoma Treatment

Published Tue, Oct 15 2024 2:36 PM UTC

The battle against glioblastoma, one of the most aggressive and lethal forms of brain cancer, has seen a surge of innovative approaches in drug discovery and development. Lantern Pharma Inc., an artificial intelligence (AI) company focused on revolutionizing oncology therapies, has recently made significant strides in this arena. The U.S. Food and Drug Administration (FDA) ...

Business Update

Harnessing Artificial Intelligence in Pediatric Oncology Lantern Pharmas Innovations in Targeted Therapies

Published Mon, Sep 23 2024 1:47 PM UTC

Pediatric cancers, while rare, present significant challenges in terms of diagnosis and treatment. Among these, malignant rhabdoid tumors (MRT) and rhabdomyosarcoma are particularly aggressive and require urgent attention for innovative therapeutic strategies. Lantern Pharma Inc., a clinical-stage biopharmaceutical company based in Dallas, is making substantial strides in th...

Business Update

In recent developments that promise a transformative impact on oncology drug development, Lant...

Published Wed, Aug 7 2024 2:47 PM UTC

Harnessing AI Innovation in Oncology: Lantern Pharma s Breakthroughs in Cancer Treatment Synergy and Development In recent developments that promise a transformative impact on oncology drug development, Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of integrating artificial intelligence (AI) and machine learning (ML) into the...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com